{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:38:36Z","timestamp":1791329916605,"version":"4.3.1"},"reference-count":126,"publisher":"National Institute for Health and Care Research","issue":"40","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/142\/02"],"award-info":[{"award-number":["11\/142\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule required after initial treatment has associated costs for patients and the NHS. In photodynamic diagnosis, before transurethral resection of bladder tumour, a photosensitiser that is preferentially absorbed by tumour cells is instilled intravesically. Transurethral resection of bladder tumour is then conducted under blue light, causing the photosensitiser to fluoresce. Photodynamic diagnosis-guided transurethral resection of bladder tumour offers better diagnostic accuracy than standard white-light-guided transurethral resection of bladder tumour, potentially reducing the chance of subsequent recurrence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The objective was to assess the clinical effectiveness and cost-effectiveness of photodynamic diagnosis-guided transurethral resection of bladder tumour.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n This was a multicentre, pragmatic, open-label, parallel-group, non-masked, superiority randomised controlled trial. Allocation was by remote web-based service, using a 1\u2009:\u20091 ratio and a minimisation algorithm balanced by centre and sex.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n The setting was 22 NHS hospitals.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Patients aged \u2265\u200916 years with a suspected first diagnosis of high-risk non-muscle-invasive bladder cancer, no contraindications to photodynamic diagnosis and written informed consent were eligible.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Photodynamic diagnosis-guided transurethral resection of bladder tumour and standard white-light cystoscopy transurethral resection of bladder tumour.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary clinical outcome measure was the time to recurrence from the date of randomisation to the date of pathologically proven first recurrence (or intercurrent bladder cancer death). The primary health economic outcome was the incremental cost per quality-adjusted life-year gained at 3 years.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We enrolled 538 participants from 22 UK hospitals between 11 November 2014 and 6 February 2018. Of these, 269 were allocated to photodynamic diagnosis and 269 were allocated to white light. A total of 112 participants were excluded from the analysis because of ineligibility (n<\/jats:italic>\u2009=\u20095), lack of non-muscle-invasive bladder cancer diagnosis following transurethral resection of bladder tumour (n<\/jats:italic>\u2009=\u200989) or early cystectomy (n<\/jats:italic>\u2009=\u200918). In total, 209 photodynamic diagnosis and 217 white-light participants were included in the clinical end-point analysis population. All randomised participants were included in the cost-effectiveness analysis. Over a median follow-up period of 21 months for the photodynamic diagnosis group and 22 months for the white-light group, there were 86 recurrences (3-year recurrence-free survival rate 57.8%, 95% confidence interval 50.7% to 64.2%) in the photodynamic diagnosis group and 84 recurrences (3-year recurrence-free survival rate 61.6%, 95% confidence interval 54.7% to 67.8%) in the white-light group (hazard ratio 0.94, 95% confidence interval 0.69 to 1.28; p<\/jats:italic>\u2009=\u20090.70). Adverse event frequency was low and similar in both groups [12 (5.7%) in the photodynamic diagnosis group vs. 12 (5.5%) in the white-light group]. At 3 years, the total cost was \u00a312,881 for photodynamic diagnosis-guided transurethral resection of bladder tumour and \u00a312,005 for white light. There was no evidence of differences in the use of health services or total cost at 3 years. At 3 years, the quality-adjusted life-years gain was 2.094 in the photodynamic diagnosis transurethral resection of bladder tumour group and 2.087 in the white light group. The probability that photodynamic diagnosis-guided transurethral resection of bladder tumour was cost-effective was never >\u200930% over the range of society\u2019s cost-effectiveness thresholds.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Fewer patients than anticipated were correctly diagnosed with intermediate- to high-risk non-muscle-invasive bladder cancer before transurethral resection of bladder tumour and the ratio of intermediate- to high-risk non-muscle-invasive bladder cancer was higher than expected, reducing the number of observed recurrences and the statistical power.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Photodynamic diagnosis-guided transurethral resection of bladder tumour did not reduce recurrences, nor was it likely to be cost-effective compared with white light at 3 years. Photodynamic diagnosis-guided transurethral resection of bladder tumour is not supported in the management of primary intermediate- to high-risk non-muscle-invasive bladder cancer.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Further work should include the modelling of appropriate surveillance schedules and exploring predictive and prognostic biomarkers.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n This trial is registered as ISRCTN84013636.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 26, No. 40. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/plpu1526","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T11:55:12Z","timestamp":1666871712000},"page":"1-144","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn84013636","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1952-7462","authenticated-orcid":true,"given":"Rakesh","family":"Heer","sequence":"first","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-5263","authenticated-orcid":true,"given":"Rebecca","family":"Lewis","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-006X","authenticated-orcid":true,"given":"Anne","family":"Duncan","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-0236","authenticated-orcid":true,"given":"Steven","family":"Penegar","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-6289","authenticated-orcid":true,"given":"Thenmalar","family":"Vadiveloo","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0065-1463","authenticated-orcid":true,"given":"Emma","family":"Clark","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-2501","authenticated-orcid":true,"given":"Ge","family":"Yu","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-4640","authenticated-orcid":true,"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[{"name":"Department of Urology, Western General Hospital, NHS Lothian, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-0339","authenticated-orcid":true,"given":"Joanne","family":"Cresswell","sequence":"additional","affiliation":[{"name":"Department of Urology, South Tees Hospitals NHS Trust, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-9912","authenticated-orcid":true,"given":"John","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Urology, Royal Devon and Exeter Hospital NHS Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-0081","authenticated-orcid":true,"given":"James","family":"N\u2019Dow","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-5195","authenticated-orcid":true,"given":"Ghulam","family":"Nabi","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-2929","authenticated-orcid":true,"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[{"name":"Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7036-1923","authenticated-orcid":true,"given":"John","family":"Kelly","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-7349","authenticated-orcid":true,"given":"Craig","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Health Services Research Unit, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-2983","authenticated-orcid":true,"given":"Henry","family":"Lazarowicz","sequence":"additional","affiliation":[{"name":"Department of Urology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-5778","authenticated-orcid":true,"given":"Angela","family":"Allan","sequence":"additional","affiliation":[{"name":"Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-6767","authenticated-orcid":true,"given":"Matthew","family":"Breckons","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-8991","authenticated-orcid":true,"given":"Karen","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6440-6486","authenticated-orcid":true,"given":"Louise","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-0498","authenticated-orcid":true,"given":"Andy","family":"Feber","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0256-2889","authenticated-orcid":true,"given":"Alison","family":"McDonald","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-9252","authenticated-orcid":true,"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-7318","authenticated-orcid":true,"given":"Giovany","family":"Orozco-Leal","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-0813","authenticated-orcid":true,"given":"Stephen","family":"Rice","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-3656","authenticated-orcid":true,"given":"Zafer","family":"Tandogdu","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Taylor","sequence":"additional","affiliation":[{"name":"Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-2230","authenticated-orcid":true,"given":"Laura","family":"Wilson","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8429","authenticated-orcid":true,"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-5646","authenticated-orcid":true,"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-5020","authenticated-orcid":true,"given":"Emma","family":"Hall","sequence":"additional","affiliation":[{"name":"Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"key20221027125056753_ref1-bib1","doi-asserted-by":"publisher","first-page":"e022268","DOI":"10.1136\/bmjopen-2018-022268","article-title":"Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness","volume":"9","author":"Tandogdu","year":"2019","journal-title":"BMJ Open"},{"key":"key20221027125056753_ref1-bib2","volume-title":"Bladder Cancer Statistics","author":"Cancer Research UK","year":"2020"},{"key":"key20221027125056753_ref1-bib3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1464-410X.2002.02880.x","article-title":"Does smoking status influence the prognosis of bladder cancer? A systematic review","volume":"90","author":"Aveyard","year":"2002","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10552-005-0389-0","article-title":"A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women","volume":"17","author":"Puente","year":"2006","journal-title":"Cancer Causes Control"},{"key":"key20221027125056753_ref1-bib5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/bjc.2011.430","article-title":"Cancer incidence in the United Kingdom: projections to the year 2030","volume":"105","author":"Mistry","year":"2011","journal-title":"Br J Cancer"},{"key":"key20221027125056753_ref1-bib6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"key20221027125056753_ref1-bib7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1464-410X.2006.05976.x","article-title":"A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic","volume":"97","author":"Edwards","year":"2006","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0022-5347(05)67916-5","article-title":"A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice","volume":"163","author":"Khadra","year":"2000","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1308\/003588410X12664192076935","article-title":"Mechanisms of recurrence of Ta\/T1 bladder cancer","volume":"92","author":"Bryan","year":"2010","journal-title":"Ann R Coll Surg Engl"},{"key":"key20221027125056753_ref1-bib10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"key20221027125056753_ref1-bib12","volume-title":"Non-muscle-invasive Bladder Cancer","author":"European Association of Urology","year":"2021"},{"key":"key20221027125056753_ref1-bib13","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib15","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1097\/01.ju.0000034450.80198.1c","article-title":"Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.ju.0000039680.90768.b3","article-title":"Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","article-title":"Intravesical bacillus Calmette\u2013Guerin in Ta and T1 bladder cancer","volume":"4","author":"Shelley","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221027125056753_ref1-bib18","unstructured":"National Institute for Health and Care Excellence (NICE). Bladder Cancer: Diagnosis and Management. NICE Guideline [NG2]. London: NICE; 2015. URL: www.nice.org.uk\/guidance\/ng2 (accessed 11 June 2021)."},{"key":"key20221027125056753_ref1-bib19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1464-410X.2005.05249.x","article-title":"The economic consequences of prostate and bladder cancer in the UK","volume":"95","author":"Sangar","year":"2005","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/01.ju.0000149080.82697.65","article-title":"Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature","volume":"173","author":"Porter","year":"2005","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bju.15008","article-title":"Exploring patients\u2019 experience and perception of being diagnosed with bladder cancer: a mixed-methods approach","volume":"125","author":"Tan","year":"2020","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.urology.2004.09.050","article-title":"Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey","volume":"65","author":"Yoshimura","year":"2005","journal-title":"Urology"},{"key":"key20221027125056753_ref1-bib25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1464-410X.2005.05604.x","article-title":"Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy","volume":"96","author":"Zaak","year":"2005","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/01.ju.0000075054.38441.2d","article-title":"Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer","volume":"170","author":"Marti","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"key20221027125056753_ref1-bib27","doi-asserted-by":"publisher","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"key20221027125056753_ref1-bib28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cncr.25523","article-title":"Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial","volume":"117","author":"Stenzl","year":"2011","journal-title":"Cancer"},{"key":"key20221027125056753_ref1-bib29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.juro.2010.06.148","article-title":"Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer","volume":"184","author":"Stenzl","year":"2010","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","article-title":"Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy","volume":"188","author":"Grossman","year":"2012","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"key20221027125056753_ref1-bib32","unstructured":"National Cancer Institute. CTCAEs v4: Common Terminology Criteria for Adverse Events (CTCAE). Rockville, MD: National Cancer Institute; 2010. URL: http:\/\/ctep.cancer.gov\/ (accessed 12 February 2021)."},{"key":"key20221027125056753_ref1-bib33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"key20221027125056753_ref1-bib34","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. Process and Methods [PMG9]. London: NICE; 2013. URL: www.nice.org.uk\/process\/pmg9 (accessed June 2021)."},{"key":"key20221027125056753_ref1-bib35","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: an application of the non-parametric bootstrap","volume":"19","author":"Barber","year":"2000","journal-title":"Stat Med"},{"key":"key20221027125056753_ref1-bib36","unstructured":"Joint Formulary Committee. British National Formulary. 76th edn. London: BMJ Group and Pharmaceutical Press; 2018."},{"key":"key20221027125056753_ref1-bib37","unstructured":"NHS Improvement. NHS Reference Costs 2018\u201319. London: NHS Improvement; 2019."},{"key":"key20221027125056753_ref1-bib38","volume-title":"Unit Costs of Health and Social Care","author":"Curtis","year":"2018"},{"key":"key20221027125056753_ref1-bib39","volume-title":"World Economic Outlook Database (October 2018)","author":"International Monetary Fund"},{"key":"key20221027125056753_ref1-bib40","unstructured":"Department of Transport. Transport Analysis Guidance (TAG) Data Book v1.13. 1. London: Department for Transport; 2020. URL: www.gov.uk\/government\/publications\/tag-data-book (accessed June 2021)."},{"key":"key20221027125056753_ref1-bib41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20221027125056753_ref1-bib42","doi-asserted-by":"publisher","first-page":"d40","DOI":"10.1136\/bmj.d40","article-title":"Strategy for intention to treat analysis in randomised trials with missing outcome data","volume":"342","author":"White","year":"2011","journal-title":"BMJ"},{"key":"key20221027125056753_ref1-bib43","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"key20221027125056753_ref1-bib44","volume-title":"Econometric Analysis: Global Edition","author":"Greene","year":"2014"},{"key":"key20221027125056753_ref1-bib45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","article-title":"Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation","volume":"6","author":"Briggs","year":"1997","journal-title":"Health Econ"},{"issue":"2","key":"key20221027125056753_ref1-bib46","doi-asserted-by":"publisher","DOI":"10.3310\/hta3020","article-title":"Handling uncertainty when performing economic evaluation of healthcare interventions","volume":"3","author":"Briggs","year":"1999","journal-title":"Health Technol Assess"},{"key":"key20221027125056753_ref1-bib47","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","article-title":"Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies","volume":"23","author":"Briggs","year":"2002","journal-title":"Annu Rev Public Health"},{"key":"key20221027125056753_ref1-bib48","unstructured":"National Research Council. Principles and Methods of Sensitivity Analyses. In National Research Council (US) Panel on Handling Missing Data in Clinical Trials, editor. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: Academies Press (US); 2010."},{"key":"key20221027125056753_ref1-bib49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/01621459.1993.10594302","article-title":"Pattern-mixture models for multivariate incomplete data","volume":"88","author":"Little","year":"1993","journal-title":"J Am Stat Assoc"},{"key":"key20221027125056753_ref1-bib50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pst.1549","article-title":"Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models","volume":"12","author":"Ratitch","year":"2013","journal-title":"Pharm Stat"},{"key":"key20221027125056753_ref1-bib51","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1002\/sim.6753","article-title":"Sensitivity analysis for missing data in regulatory submissions","volume":"35","author":"Permutt","year":"2016","journal-title":"Stat Med"},{"key":"key20221027125056753_ref1-bib52","doi-asserted-by":"publisher","first-page":"10.","DOI":"10.1056\/EVIDoa2200092","article-title":"Randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"key":"key20221027125056753_ref1-bib53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT \u2013 a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib54","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","article-title":"A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib55","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib56","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.urology.2017.08.007","article-title":"Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study","volume":"109","author":"Mariappan","year":"2017","journal-title":"Urology"},{"key":"key20221027125056753_ref1-bib57","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","article-title":"Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel","volume":"6","author":"Soukup","year":"2020","journal-title":"Eur Urol Focus"},{"key":"key20221027125056753_ref1-bib59","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bju.12495","article-title":"Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy","volume":"114","author":"Lammers","year":"2014","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib64","first-page":"6269","article-title":"Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride?","volume":"19","author":"Gravas","year":"2012","journal-title":"Can J Urol"},{"key":"key20221027125056753_ref1-bib65","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000328218","article-title":"Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics","volume":"87","author":"Kruck","year":"2011","journal-title":"Urol Int"},{"key":"key20221027125056753_ref1-bib66","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/bju.12355","article-title":"Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer","volume":"112","author":"O\u2019Brien","year":"2013","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib67","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/j.1464-410X.2011.10571.x","article-title":"Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking","volume":"109","author":"Mariappan","year":"2012","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2020.06.051","article-title":"Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland\u2019s Quality Performance Indicators Programme","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.eururo.2009.11.041","article-title":"Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies","volume":"57","author":"Kausch","year":"2010","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib70","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib71","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/photob.2019.4634","article-title":"Hexaminolevulinate in the management of nonmuscle invasive bladder cancer: a meta-analysis","volume":"37","author":"Konecki","year":"2019","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"key20221027125056753_ref1-bib73","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s00345-017-2077-6","article-title":"\u2018Real-life experience\u2019: recurrence rate at 3 years with Hexvix\u00ae photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study","volume":"35","author":"Gallagher","year":"2017","journal-title":"World J Urol"},{"key":"key20221027125056753_ref1-bib74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.urology.2015.04.015","article-title":"Real-life experience: early recurrence with Hexvix\u00ae photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer","volume":"86","author":"Mariappan","year":"2015","journal-title":"Urology"},{"key":"key20221027125056753_ref1-bib75","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.eururo.2014.06.037","article-title":"Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations","volume":"66","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib76","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bju.13020","article-title":"Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study","volume":"116","author":"Palou","year":"2015","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrurol.2014.245","article-title":"Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA","volume":"11","author":"Daneshmand","year":"2014","journal-title":"Nat Rev Urol"},{"key":"key20221027125056753_ref1-bib79","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"key":"key20221027125056753_ref1-bib80","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.eururo.2016.11.023","article-title":"Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree","volume":"71","author":"Sylvester","year":"2017","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/BLC-150034","article-title":"Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE)","volume":"2","author":"Power","year":"2016","journal-title":"Bladder Cancer"},{"key":"key20221027125056753_ref1-bib82","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/2051415818757339","article-title":"The management of non-muscle-invasive bladder cancer: a comparison of European and UK guidelines","volume":"11","author":"Leiblich","year":"2018","journal-title":"J Clin Urol"},{"key":"key20221027125056753_ref1-bib83","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib84","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.euf.2017.09.002","article-title":"Discrepancy between European Association of Urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey","volume":"5","author":"Hendricksen","year":"2019","journal-title":"Eur Urol Focus"},{"key":"key20221027125056753_ref1-bib85","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette\u2013Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"key20221027125056753_ref1-bib86","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette\u2013Gu\u00e9rin, and bacillus Calmette\u2013Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"key20221027125056753_ref1-bib88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus Calmette\u2013Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib89","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib91","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.7150\/jca.34527","article-title":"Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer","volume":"11","author":"Chen","year":"2020","journal-title":"J Cancer"},{"key":"key20221027125056753_ref1-bib92","doi-asserted-by":"publisher","first-page":"e028173","DOI":"10.1136\/bmjopen-2018-028173","article-title":"Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis","volume":"9","author":"Chen","year":"2019","journal-title":"BMJ Open"},{"key":"key20221027125056753_ref1-bib93","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00120-019-01037-3","article-title":"The development of real-time multispectral imaging for the diagnostics of bladder cancer","volume":"58","author":"Bolenz","year":"2019","journal-title":"Urologe A"},{"key":"key20221027125056753_ref1-bib94","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00464-018-6578-1","article-title":"Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review","volume":"33","author":"Brunckhorst","year":"2019","journal-title":"Surg Endosc"},{"key":"key20221027125056753_ref1-bib95","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1089\/end.2020.0919","article-title":"Cystoscopic imaging for bladder cancer detection based on stepwise organic transfer learning with a pretrained convolutional neural network","volume":"35","author":"Ikeda","year":"2021","journal-title":"J Endourol"},{"key":"key20221027125056753_ref1-bib96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2018.05.012","article-title":"Novel urinary biomarkers for the detection of bladder cancer: a systematic review","volume":"69","author":"Tan","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"key20221027125056753_ref1-bib97","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.juro.2016.01.102","article-title":"Dynamic prognostication using conditional recurrence and progression estimates for patients with nonmuscle invasive bladder cancer","volume":"196","author":"Leitner","year":"2016","journal-title":"J Urol"},{"key":"key20221027125056753_ref1-bib98","doi-asserted-by":"publisher","first-page":"39.e21","DOI":"10.1016\/j.urolonc.2019.10.003","article-title":"External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system","volume":"38","author":"Leo","year":"2020","journal-title":"Urol Oncol"},{"key":"key20221027125056753_ref1-bib99","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"key20221027125056753_ref1-bib100","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette\u2013Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"key20221027125056753_ref1-bib101","volume-title":"BAUS Data & Audit Programme","author":"British Association of Urological Surgeons"},{"key":"key20221027125056753_ref1-bib102","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pdpdt.2008.05.001","article-title":"The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer","volume":"5","author":"Dindyal","year":"2008","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"key20221027125056753_ref1-bib103","unstructured":"National Institute for Health and Care Excellence (NICE). Narrow Band Imaging for Barrett\u2019s Oesophagus. Medtech Innovation Briefing [MIB179]. London: NICE; 2019. URL: www.nice.org.uk\/advice\/mib179 (accessed 11 June 2021)."},{"key":"key20221027125056753_ref1-bib104","volume-title":"Unit Costs of Health and Social Care","author":"Curtis","year":"2009"},{"key":"key20221027125056753_ref1-bib105","unstructured":"National Audit Office. Out-of-Hours GP Services in England. London: National Audit Office; 2014. URL: www.nao.org.uk\/serarch\/out-of-hours\/ (accessed 12 January 2022)."},{"key":"key20221027125056753_ref1-bib106","volume-title":"Travel \u2013 Mileage and Fuel Rates and Allowances","author":"HM Revenue and Customs","year":"2019"},{"key":"key20221027125056753_ref1-bib107","unstructured":"Department of Health and Social Care. NHS Reference Costs 2009\u20132010. London: Department of Health and Social Care; 2011. URL: www.gov.uk\/government\/publications\/nhs-reference-costs-2009-2010 (accessed 11 June 2021)."},{"key":"key20221027125056753_ref1-bib108","unstructured":"Office for National Statistics (ONS). Annual Survey of Hours and Earnings Time Series of Selected Estimates. Newport: ONS; 2020. URL: www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/datasets\/ashe1997to2015selectedestimates (accessed 11 June 2021)."},{"key":"key20221027125056753_ref1-bib109","unstructured":"NHS Pay Review Body. NHS Pay Review Body Twenty-sixth Report 2012. London: The Stationery Office; 2012. URL: www.gov.uk\/government\/publications\/nhs-pay-review-body-twenty-sixth-report-2012 (accessed 11 June 2021)."},{"key":"key20221027125056753_ref1-bib110","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"key20221027125056753_ref1-bib111","unstructured":"Office for National Statistics (ONS). National Life Tables, UK: 2016 to 2018. Newport: ONS; 2019. URL: www.ons.gov.uk\/releases\/nationallifetablesuk2016to2018 (accessed June 2021)."},{"key":"key20221027125056753_ref1-bib112","unstructured":"EuroQol Research Foundation. EQ-5D-3L User Guide, 2018. Rotterdam: EuroQol Research Foundation; 2018."},{"key":"key20221027125056753_ref1-bib113","volume-title":"NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-effectiveness Models","author":"Kaltenthaler","year":"2011"},{"key":"key20221027125056753_ref1-bib114","volume-title":"Applied Methods of Cost-Effectiveness Analysis in Healthcare","author":"Gray","year":"2011"},{"key":"key20221027125056753_ref1-bib115","unstructured":"Committee for Medicinal Products for Human Use. Guideline on Adjustment for Baseline Covariates in Clinical Trials. London: European Medicines Agency; 2015."},{"key":"key20221027125056753_ref1-bib116","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-018-0084-1","article-title":"Conducting a time trade-off study alongside a clinical trial: a case study and recommendations","volume":"3","author":"Shen","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"key20221027125056753_ref1-bib117","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0167-6296(95)00038-0","article-title":"Valuing health states: a comparison of methods","volume":"15","author":"Dolan","year":"1996","journal-title":"J Health Econ"},{"key":"key20221027125056753_ref1-bib118","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jval.2018.10.002","article-title":"Valuation of health states considered to be worse than death \u2013 an analysis of composite time trade-off data from 5 EQ-5D-5L valuation studies","volume":"22","author":"Gandhi","year":"2019","journal-title":"Value Health"},{"key":"key20221027125056753_ref1-bib119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","article-title":"Measurement of health state utilities for economic appraisal: a review","volume":"5","author":"Torrance","year":"1986","journal-title":"J Health Econ"},{"key":"key20221027125056753_ref1-bib120","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","article-title":"Introducing the composite time trade-off: a test of feasibility and face validity","volume":"14","author":"Janssen","year":"2013","journal-title":"Eur J Health Econ"},{"key":"key20221027125056753_ref1-bib121","volume-title":"Time Trade-off User Manual: Props and Self-completion Methods","author":"Gudex","year":"1994"},{"key":"key20221027125056753_ref1-bib122","doi-asserted-by":"publisher","first-page":"23897","DOI":"10.3390\/ijms151223897","article-title":"The promise of novel molecular markers in bladder cancer","volume":"15","author":"Miremami","year":"2014","journal-title":"Int J Mol Sci"},{"key":"key20221027125056753_ref1-bib123","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"key20221027125056753_ref1-bib124","unstructured":"Great Britain. Human Tissue Act 2004. London: The Stationery Office; 2004."},{"key":"key20221027125056753_ref1-bib125","volume-title":"Hyperthermia for Intermediate risk bladder cancer (HIVEC-II)","author":"NHS Health Research Authority"},{"key":"key20221027125056753_ref1-bib126","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3758-7","article-title":"DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells","volume":"17","author":"Tan","year":"2017","journal-title":"BMC Cancer"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040476","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/PLPU1526\/PLPU1526.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2040476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:40:11Z","timestamp":1692114011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/PLPU1526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":126,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["10.3310\/PLPU1526"],"URL":"https:\/\/doi.org\/10.3310\/plpu1526","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"6-2014","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"2-2021","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"7-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}